| Trial ID: | L1553 |
| Source ID: | NCT00413101
|
| Associated Drug: |
Epoetin Beta [Neorecormon]
|
| Title: |
A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Anemia
|
| Interventions: |
DRUG: epoetin beta [NeoRecormon]
|
| Outcome Measures: |
Primary: Hb level, BP., Throughout study|LVMI ejection fraction, ejection fraction., 12 months | Secondary: SAEs, AEs leading to withdrawal, AEs related to NeoRecormon., Throughout study
|
| Sponsor/Collaborators: |
Sponsor: Hoffmann-La Roche
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
|
| Completion Date: |
2008-03
|
| Results First Posted: |
|
| Last Update Posted: |
2009-05-14
|
| Locations: |
Novi Sad, 21000, Serbia
|
| URL: |
https://clinicaltrials.gov/show/NCT00413101
|
